CSL Ltd
ASX:CSL

Watchlist Manager
CSL Ltd Logo
CSL Ltd
ASX:CSL
Watchlist
Price: 276.47 AUD 1% Market Closed
Market Cap: 133.9B AUD
Have any thoughts about
CSL Ltd?
Write Note

CSL Ltd
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

CSL Ltd
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
CSL Ltd
ASX:CSL
Revenue
$14.8B
CAGR 3-Years
13%
CAGR 5-Years
12%
CAGR 10-Years
10%
Immutep Ltd
ASX:IMM
Revenue
AU$119.6k
CAGR 3-Years
-27%
CAGR 5-Years
-54%
CAGR 10-Years
-27%
Mesoblast Ltd
ASX:MSB
Revenue
$5.9m
CAGR 3-Years
-7%
CAGR 5-Years
-19%
CAGR 10-Years
N/A
Clinuvel Pharmaceuticals Ltd
ASX:CUV
Revenue
AU$95.5m
CAGR 3-Years
25%
CAGR 5-Years
25%
CAGR 10-Years
41%
Telix Pharmaceuticals Ltd
ASX:TLX
Revenue
AU$502.5m
CAGR 3-Years
359%
CAGR 5-Years
381%
CAGR 10-Years
N/A
PYC Therapeutics Ltd
ASX:PYC
Revenue
AU$22.9m
CAGR 3-Years
93%
CAGR 5-Years
882%
CAGR 10-Years
42%
No Stocks Found

CSL Ltd
Glance View

Market Cap
133.6B AUD
Industry
Biotechnology

CSL Ltd. is a global biotechnology powerhouse, rooted in Australia, that specializes in developing and delivering innovative therapies for people with serious and rare medical conditions. Founded in 1916, CSL originally focused on producing blood serum for treating was patients during World War I. Over the years, the company has evolved remarkably, moving into the biopharmaceutical realm with a strong focus on immunology, hematology, and respiratory diseases. Today, CSL is best known for its leading product, antibody therapies derived from human plasma, providing vital treatments for conditions such as hemophilia, primary immunodeficiency, and Guillain-Barré Syndrome. Investors appreciate CSL’s impressive track record of steady revenue growth, driven by increasing global demand for its life-saving products and a robust pipeline of new therapies under development. What sets CSL apart in the competitive landscape is its commitment to research and development, dedicating a significant portion of its resources to innovation that improves patient outcomes. The company's diverse global presence in over 30 countries allows it to effectively tap into various markets, making it a resilient choice for investors. With an experienced leadership team at the helm and a strong focus on sustainability and ethical practice, CSL has garnered a reputation for quality and consistency. As healthcare becomes an increasingly essential part of economies worldwide, CSL stands out with its strategic investments and partnerships aimed at expanding its market reach. For investors, CSL Ltd. represents not just a stable growth opportunity, but a chance to be part of a mission-driven organization making a significant impact on global health.

CSL Intrinsic Value
221.34 AUD
Overvaluation 20%
Intrinsic Value
Price

See Also

What is CSL Ltd's Revenue?
Revenue
14.8B USD

Based on the financial report for Jun 30, 2024, CSL Ltd's Revenue amounts to 14.8B USD.

What is CSL Ltd's Revenue growth rate?
Revenue CAGR 10Y
10%

Over the last year, the Revenue growth was 11%. The average annual Revenue growth rates for CSL Ltd have been 13% over the past three years , 12% over the past five years , and 10% over the past ten years .

Back to Top